01 1Hovione LLC
01 1Omaveloxolone
01 1Portugal
NDC Package Code : 42052-1702
Start Marketing Date : 2024-07-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
68
PharmaCompass offers a list of Omaveloxolone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Omaveloxolone manufacturer or Omaveloxolone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Omaveloxolone manufacturer or Omaveloxolone supplier.
PharmaCompass also assists you with knowing the Omaveloxolone API Price utilized in the formulation of products. Omaveloxolone API Price is not always fixed or binding as the Omaveloxolone Price is obtained through a variety of data sources. The Omaveloxolone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Omaveloxolone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Omaveloxolone, including repackagers and relabelers. The FDA regulates Omaveloxolone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Omaveloxolone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Omaveloxolone supplier is an individual or a company that provides Omaveloxolone active pharmaceutical ingredient (API) or Omaveloxolone finished formulations upon request. The Omaveloxolone suppliers may include Omaveloxolone API manufacturers, exporters, distributors and traders.
click here to find a list of Omaveloxolone suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Omaveloxolone as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Omaveloxolone API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Omaveloxolone as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Omaveloxolone and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Omaveloxolone NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Omaveloxolone suppliers with NDC on PharmaCompass.
